semaglutide updates Novo Nordisk announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous 7.2 mg for obesity Update : r/Semaglutide

Most people tolerate both medication types well after initial adjustment

Current clinical trials of next-generation drugs indicate that some treatments possess excellent potential to overcome the MDR issue

Retatrutides triple receptor mechanism creates superior weight loss compared to existing options, but the aggressive fat loss also increases the risk of muscle catabolism

Key Research Characteristics: Extended half-life (~2030 hours vs ~1215 minutes for native IGF-1) due to reduced IGFBP binding Potent agonist at IGF-1R, studied for roles in cellular proliferation, differentiation, and survival signalling Investigated in models of muscle hypertrophy, neuroprotection, and metabolic regulation 83 amino acid analogue